Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors

M Sugahara, T Tanaka, M Nangaku - Pharmacology & Therapeutics, 2022 - Elsevier
For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …
被引用次数：32 相关文章

Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors

M Sugahara, T Tanaka… - Pharmacology & …, 2022 - pubmed.ncbi.nlm.nih.gov
For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors

M Sugahara, T Tanaka… - Pharmacology and …, 2022 - tohoku.elsevierpure.com
For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

[引用][C] Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors

M Sugahara, T Tanaka, M Nangaku - Pharmacology & Therapeutics, 2022 - cir.nii.ac.jp
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible
factor-prolyl hydroxylase inhibitors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.

M Sugahara, T Tanaka, M Nangaku - Pharmacology & Therapeutics, 2022 - europepmc.org
For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …